| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2011-07-12 10:28:56 UTC |
|---|
| Update Date | 2022-03-07 02:51:34 UTC |
|---|
| HMDB ID | HMDB0013659 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | (±)8(9)-EET Ethanolamide |
|---|
| Description | (±)8(9)-EET ethanolamide is a cytochrome P450 (CYP450) metabolite of arachidonoyl ethanolamide (AEA), although specific stereochemistry rather than a racemic mixture would likely ensue from enzymatic metabolism (PMID: 17272674 ). AEA is an endogenous lipid neurotransmitter with cannabingeric activity, binding to both the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors (PMID: 8395053 , 16078824 ). Fatty acid amide hydrolase (FAAH) is the enzyme responsible for the hydrolysis and inactivation of AEA (PMID: 12052036 ). Metabolism of AEA by COX-2, lipoxygenases, and CYP450 enzymes has also been documented (PMID: 12052037 , 17272674 ). Human liver microsomes metabolize AEA to 5,6-, 8,9-, 11,12-, and 14,15-EET ethanolamides in a time and protein concentration dependent manner (PMID: 17272674 ). (±)8(9)-EET reduces glomerular filtration rate through cyclooxygenase dependent preglomerular vasoconstriction (PMID: 1928373 ). The physiological actions of (±)8(9)-EET ethanolamide have not been examined. |
|---|
| Structure | CCCCC\C=C/C\C=C/CC1OC1C\C=C/CCCC(=O)NCCO InChI=1S/C22H37NO3/c1-2-3-4-5-6-7-8-9-12-15-20-21(26-20)16-13-10-11-14-17-22(25)23-18-19-24/h6-7,9-10,12-13,20-21,24H,2-5,8,11,14-19H2,1H3,(H,23,25)/b7-6-,12-9-,13-10- |
|---|
| Synonyms | | Value | Source |
|---|
| 8(9)-EET-ea | ChEBI | | 8(9)-EpETrE-ea | ChEBI | | 8,9-EET-ea | ChEBI | | N-(8,9-Epoxy-5Z,11Z,14Z-eicosatrienoyl)-ethanolamine | ChEBI | | N-(8,9-Epoxy-5Z,11Z,14Z-icosatrienoyl)ethanolamine | ChEBI | | (+/-)8(9)-epetre ethanolamide | HMDB |
|
|---|
| Chemical Formula | C22H37NO3 |
|---|
| Average Molecular Weight | 363.5341 |
|---|
| Monoisotopic Molecular Weight | 363.277344055 |
|---|
| IUPAC Name | (5Z)-N-(2-hydroxyethyl)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enamide |
|---|
| Traditional Name | 8(9)-EpETrE-EA |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CCCCC\C=C/C\C=C/CC1OC1C\C=C/CCCC(=O)NCCO |
|---|
| InChI Identifier | InChI=1S/C22H37NO3/c1-2-3-4-5-6-7-8-9-12-15-20-21(26-20)16-13-10-11-14-17-22(25)23-18-19-24/h6-7,9-10,12-13,20-21,24H,2-5,8,11,14-19H2,1H3,(H,23,25)/b7-6-,12-9-,13-10- |
|---|
| InChI Key | BXHPMUQFGGSDAK-TYAUOURKSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as n-acylethanolamines. N-acylethanolamines are compounds containing an N-acyethanolamine moiety, which is characterized by an acyl group is linked to the nitrogen atom of ethanolamine. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic nitrogen compounds |
|---|
| Class | Organonitrogen compounds |
|---|
| Sub Class | Amines |
|---|
| Direct Parent | N-acylethanolamines |
|---|
| Alternative Parents | |
|---|
| Substituents | - N-acylethanolamine
- Fatty amide
- N-acyl-amine
- Fatty acyl
- Carboxamide group
- Secondary carboxylic acid amide
- Oxacycle
- Organoheterocyclic compound
- Carboxylic acid derivative
- Dialkyl ether
- Oxirane
- Ether
- Organopnictogen compound
- Alcohol
- Organic oxygen compound
- Organooxygen compound
- Primary alcohol
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Aliphatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aliphatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.42 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 19.4103 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.2 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 34.7 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 3082.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 313.3 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 207.3 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 221.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 568.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 915.5 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 537.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 164.9 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1859.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 646.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1806.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 647.5 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 500.9 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 340.8 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 379.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| (??)8(9)-EET Ethanolamide,1TMS,isomer #1 | CCCCC/C=C\C/C=C\CC1OC1C/C=C\CCCC(=O)NCCO[Si](C)(C)C | 2985.7 | Semi standard non polar | 33892256 | | (??)8(9)-EET Ethanolamide,1TMS,isomer #2 | CCCCC/C=C\C/C=C\CC1OC1C/C=C\CCCC(=O)N(CCO)[Si](C)(C)C | 2911.3 | Semi standard non polar | 33892256 | | (±)8(9)-EET Ethanolamide,2TMS,isomer #1 | CCCCC/C=C\C/C=C\CC1OC1C/C=C\CCCC(=O)N(CCO[Si](C)(C)C)[Si](C)(C)C | 2940.6 | Semi standard non polar | 33892256 | | (±)8(9)-EET Ethanolamide,2TMS,isomer #1 | CCCCC/C=C\C/C=C\CC1OC1C/C=C\CCCC(=O)N(CCO[Si](C)(C)C)[Si](C)(C)C | 3020.2 | Standard non polar | 33892256 | | (±)8(9)-EET Ethanolamide,2TMS,isomer #1 | CCCCC/C=C\C/C=C\CC1OC1C/C=C\CCCC(=O)N(CCO[Si](C)(C)C)[Si](C)(C)C | 3097.0 | Standard polar | 33892256 | | (??)8(9)-EET Ethanolamide,1TBDMS,isomer #1 | CCCCC/C=C\C/C=C\CC1OC1C/C=C\CCCC(=O)NCCO[Si](C)(C)C(C)(C)C | 3220.9 | Semi standard non polar | 33892256 | | (??)8(9)-EET Ethanolamide,1TBDMS,isomer #2 | CCCCC/C=C\C/C=C\CC1OC1C/C=C\CCCC(=O)N(CCO)[Si](C)(C)C(C)(C)C | 3139.1 | Semi standard non polar | 33892256 | | (±)8(9)-EET Ethanolamide,2TBDMS,isomer #1 | CCCCC/C=C\C/C=C\CC1OC1C/C=C\CCCC(=O)N(CCO[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3430.2 | Semi standard non polar | 33892256 | | (±)8(9)-EET Ethanolamide,2TBDMS,isomer #1 | CCCCC/C=C\C/C=C\CC1OC1C/C=C\CCCC(=O)N(CCO[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3367.9 | Standard non polar | 33892256 | | (±)8(9)-EET Ethanolamide,2TBDMS,isomer #1 | CCCCC/C=C\C/C=C\CC1OC1C/C=C\CCCC(=O)N(CCO[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3151.2 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - (±)8(9)-EET Ethanolamide GC-MS (Non-derivatized) - 70eV, Positive | splash10-0f6t-7975000000-138caba1cc10d88b3acb | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (±)8(9)-EET Ethanolamide GC-MS (1 TMS) - 70eV, Positive | splash10-0fk9-8895200000-ff0d605a4780f0fe8a9b | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - (±)8(9)-EET Ethanolamide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (±)8(9)-EET Ethanolamide 10V, Positive-QTOF | splash10-03di-4219000000-6a4153a00d35175f07cc | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (±)8(9)-EET Ethanolamide 20V, Positive-QTOF | splash10-03di-9501000000-49546729e6f1fc39fbde | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (±)8(9)-EET Ethanolamide 40V, Positive-QTOF | splash10-03di-9300000000-e83b610335b0f604ffa2 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (±)8(9)-EET Ethanolamide 10V, Negative-QTOF | splash10-03di-0209000000-ecb21063dfd7ef100dad | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (±)8(9)-EET Ethanolamide 20V, Negative-QTOF | splash10-03dl-5309000000-6e6597f4aa6f9be887a1 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (±)8(9)-EET Ethanolamide 40V, Negative-QTOF | splash10-01ox-9400000000-a6384c85eb3f6a786050 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (±)8(9)-EET Ethanolamide 10V, Positive-QTOF | splash10-03di-5209000000-53d5fe289aac0a214cf6 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (±)8(9)-EET Ethanolamide 20V, Positive-QTOF | splash10-03dm-9103000000-2718f725d05698a31a6a | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (±)8(9)-EET Ethanolamide 40V, Positive-QTOF | splash10-000x-9100000000-3f90e9cfac2f10988867 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (±)8(9)-EET Ethanolamide 10V, Negative-QTOF | splash10-03di-0009000000-98c48b1fa4d3ad780022 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (±)8(9)-EET Ethanolamide 20V, Negative-QTOF | splash10-03dl-2129000000-908411b9c58743953841 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (±)8(9)-EET Ethanolamide 40V, Negative-QTOF | splash10-0596-9202000000-f292ca66393a75a3a56a | 2021-09-22 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Kozak KR, Marnett LJ: Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):211-20. [PubMed:12052037 ]
- Snider NT, Kornilov AM, Kent UM, Hollenberg PF: Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanolamides. J Pharmacol Exp Ther. 2007 May;321(2):590-7. Epub 2007 Feb 1. [PubMed:17272674 ]
- Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA: Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7656-60. [PubMed:8395053 ]
- Lambert DM, Fowler CJ: The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem. 2005 Aug 11;48(16):5059-87. [PubMed:16078824 ]
- Deutsch DG, Ueda N, Yamamoto S: The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):201-10. [PubMed:12052036 ]
- Katoh T, Takahashi K, Capdevila J, Karara A, Falck JR, Jacobson HR, Badr KF: Glomerular stereospecific synthesis and hemodynamic actions of 8,9-epoxyeicosatrienoic acid in rat kidney. Am J Physiol. 1991 Oct;261(4 Pt 2):F578-86. [PubMed:1928373 ]
|
|---|